Patents by Inventor Christopher Bieniarz

Christopher Bieniarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240069034
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Application
    Filed: September 27, 2023
    Publication date: February 29, 2024
    Inventors: Christopher Bieniarz, Rui Hong
  • Publication number: 20240018174
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: August 11, 2023
    Publication date: January 18, 2024
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11808770
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 7, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Rui Hong
  • Patent number: 11780863
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: October 10, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11740233
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 29, 2023
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Christopher Bieniarz, Michael Farrell, Donald D. Johnson, Jerome W. Kosmeder, Adrian E. Murillo, Chol Steven Yun, Zhanna Zhilina
  • Patent number: 11365210
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 21, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11359185
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jerome W Kosmeder, Mark Lefever, Casey A Kernag, Julia Ashworth-Sharpe, Jennifer Wong
  • Publication number: 20220041633
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 11092594
    Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, athiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 17, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, II, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
  • Publication number: 20210063411
    Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
    Type: Application
    Filed: September 15, 2020
    Publication date: March 4, 2021
    Inventors: Christopher Bieniarz, Jan Froehlich, Brian Daniel Kelly, Rui Hong, Mark Lefever, Phillip Miller, Hong Wang
  • Patent number: 10883999
    Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
    Type: Grant
    Filed: August 4, 2018
    Date of Patent: January 5, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Rui Hong, Hong Wang, Mark Lefever, Jan Froehlich, Christopher Bieniarz, Brian Daniel Kelly, Phillip Miller
  • Publication number: 20200348215
    Abstract: Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Christopher Bieniarz, Brian D. Kelly, Jerome W. Kosmeder, II, Eric J. May, Larry Morrison
  • Patent number: 10775281
    Abstract: Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Brian D. Kelly, Jerome W. Kosmeder, II, Eric J. May, Larry Morrison
  • Publication number: 20200271662
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Application
    Filed: March 4, 2020
    Publication date: August 27, 2020
    Inventors: Christopher Bieniarz, Rui Hong
  • Patent number: 10620217
    Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: April 14, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Rui Hong
  • Publication number: 20190128893
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 2, 2019
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20190127405
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 2, 2019
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20190004061
    Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
    Type: Application
    Filed: August 4, 2018
    Publication date: January 3, 2019
    Inventors: Rui Hong, Hong Wang, Mark Lefever, Jan Froehlich, Christopher Bieniarz, Brian Daniel Kelly, Phillip Miller
  • Patent number: 10168336
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 1, 2019
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Publication number: 20180372733
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Inventors: Julia Ashworth-Sharpe, Christopher Bieniarz, Michael Farrell, Donald D. Johnson, Jerome W. Kosmeder, Adrian E. Murillo, Chol Steven Yun, Zhanna Zhilina